Preclinical studies have also shown that IL-6R blockade or genetic ablation of CD8+ T cell intrinsic IL-6 signaling synergized with anti-PD-L1 therapy to enhance antitumor responses, leading to improved tumor control (6). Here, CD8A is linked to neoplasm.